Dry Eye Syndrome

Dry eye syndrome, clinically keratoconjunctivitis sicca, is one of the more common eye complaints veterans bring to VA, and it has a structural quirk that shapes every rating decision: it does not have its own diagnostic code. There is no line in 38 CFR § 4.79 that reads "dry eye." VA rates it by analogy, and in practice the codes that do the work are DC 6018 (chronic conjunctivitis) and DC 6025 (disorders of the lacrimal apparatus).

That rating-by-analogy structure is the whole game. Because there is no dedicated code, the rating turns on two things: whether the condition is currently active with objective findings, and whether you need continuous treatment to control it. Prescription drops like cyclosporine, punctal plugs, autologous serum tears, these are not just treatment. In a dry eye claim they are evidence that the condition is active and ongoing rather than resolved. An exam that records "dry eye, stable" without documenting the active findings or the treatment burden produces a thinner rating than the condition warrants.

This page walks through how dry eye gets mapped onto DC 6018 and DC 6025 under § 4.79, what "active" versus "inactive" means for the rating, what the eye C&P exam has to measure, and the secondary chains that matter most: dry eye caused by medications you take for a service-connected condition, by Sjogren's syndrome, by chronic blepharitis, or by refractive eye surgery. I will be conservative on exact percentage tiers, because the General Rating Formula for the eye is structured around active disease and residuals rather than a simple symptom ladder, and the precise number depends on findings the regulation defines.

TL;DR

• Dry eye syndrome (keratoconjunctivitis sicca) has no dedicated diagnostic code. VA rates it by analogy under 38 CFR § 4.79, most often through DC 6018 (chronic conjunctivitis) or DC 6025 (disorders of the lacrimal apparatus).
• Under DC 6018, active chronic conjunctivitis with objective findings warrants a compensable rating; when inactive, it is rated on residuals such as visual impairment or scarring.
• DC 6025 covers disorders of the lacrimal apparatus (epiphora, dacryocystitis), with the rating depending on whether one or both eyes are affected.
• The two levers are the same in every dry eye claim: active objective findings on exam, and the need for continuous treatment (prescription drops, punctal plugs, autologous serum).
• Rather than quote exact tier percentages that vary with the regulation's active-disease and residuals structure, this page describes the mechanics and points you to the current § 4.79 text.
• Common secondary chains under § 3.310: dry eye from medications (antidepressants, antihistamines, isotretinoin), from Sjogren's syndrome, from chronic conjunctivitis or blepharitis, and from refractive surgery.
• In Claim Raven's analysis of 500 BVA dry eye cases, 46.4% were granted, 12.0% remanded, and 41.6% denied. Of the 426 cases with a C&P adequacy determination, 26.3% had the exam flagged as inadequate. Those are among the lower C&P-inadequate and remand shares across the conditions I analyzed, which fits a condition built on relatively simple objective findings.

How Dry Eye Gets Rated by Analogy Under § 4.79

The eye rating schedule lives in 38 CFR § 4.79, the schedule of ratings for the organs of special sense. It is organized around named diagnoses, and dry eye syndrome is not one of them. When a condition has no listed code, VA rates it by analogy to the most closely related listed condition under 38 CFR § 4.20.

For dry eye, two analogous codes dominate.

DC 6018, chronic conjunctivitis. This is the most common landing spot. Dry eye and chronic conjunctivitis share the inflammatory, irritation-driven presentation of the conjunctiva, so the analogy holds. The structure of DC 6018 is what matters: it distinguishes between active disease and inactive disease. When the conjunctivitis is active with objective findings, such as injection, discharge, or other observable inflammation, it warrants a compensable rating. When it is inactive, it is rated on residuals, meaning whatever lasting impairment remains, such as visual impairment or conjunctival scarring.

DC 6025, disorders of the lacrimal apparatus. This code covers problems with the tear-production and tear-drainage system: epiphora (excessive tearing from poor drainage), dacryocystitis (infection of the tear sac), and related conditions. The rating under DC 6025 depends on whether the disorder affects one eye or both. For dry eye driven by lacrimal gland dysfunction or tear-film instability rather than conjunctival inflammation, DC 6025 can be the better analogy.

Which code a rater chooses is not always obvious, and it can change the rating. The right analogy depends on the dominant pathology in your record. If the clinical picture is inflammatory conjunctival disease, DC 6018 fits. If it is a tear-system disorder, DC 6025 fits. The medical evidence should make the dominant mechanism clear so the rater applies the code that actually matches your condition.

I am deliberately not quoting exact percentage tiers for these codes here. The eye schedule was substantially revised, and the active-versus-inactive and one-eye-versus-both-eyes distinctions interact with the General Rating Formula in ways where an invented number would do more harm than good. Read the current text of § 4.79 for the operative figures, and confirm which code your rating decision actually applied.

The Two Levers: Active Findings and Continuous Treatment

Strip away the code-selection question and dry eye ratings come down to two levers.

Active objective findings. The rating distinguishes active disease from inactive disease. "Active" is not how you feel on a bad day. It is what the examiner can objectively observe and measure: conjunctival injection, reduced tear production, corneal staining showing dry-eye damage, tear-film breakup, discharge. If the exam documents active findings, the condition is rated as active. If the exam records only that you reported symptoms, with no objective findings noted, the rater may treat the condition as inactive and rate on residuals alone.

Continuous treatment. This is the lever veterans most often underuse. The need for ongoing treatment to control the condition is itself evidence that the disease is active and chronic rather than a resolved episode. Prescription drops such as cyclosporine (Restasis) or lifitegrast (Xiidra), punctal plugs that block tear drainage to keep the eye moist, and autologous serum tears made from your own blood are all treatments reserved for persistent, clinically significant dry eye. When the record documents that you depend on these to function, it supports the active, continuous nature of the condition.

The cases where these two levers come together cleanly tend to do well. An eye exam that records measured tear production, corneal staining, and a documented prescription regimen gives the rater the active findings and the treatment burden in one place. An exam that says "dry eye, on artificial tears, stable" gives the rater very little: over-the-counter artificial tears do not carry the same evidentiary weight as a prescription regimen, and "stable" reads as inactive.

C&P Exam Mechanics: What the Eye Examiner Has to Measure

The dry eye C&P exam follows the DBQ for eye conditions. For dry eye specifically, the findings that drive the rating are the objective tear-film and ocular-surface measurements, not just a recitation of symptoms.

A complete eye exam for dry eye should record:

• Visual acuity, corrected and uncorrected, for each eye
• Tear production testing, such as a Schirmer test measuring tear volume
• Tear-film stability, such as tear breakup time
• Ocular surface staining (fluorescein or lissamine green) showing corneal or conjunctival damage
• Objective signs of inflammation: conjunctival injection, discharge, lid-margin disease
• Current treatment regimen, including prescription drops, punctal plugs, or serum tears
• Any visual impairment or scarring residuals from the chronic disease

When all of these are in the report, the rater has what they need to apply DC 6018 or DC 6025 and to decide active versus inactive. When the exam is sparse, recording only that the veteran reports dryness and uses artificial tears, the rater defaults to a minimal or non-compensable rating. The objective tests are the difference between a documented active condition and an undocumented complaint.

It is worth noting that dry eye is a condition with relatively simple, reproducible objective findings compared to many of the conditions I have analyzed. A Schirmer test and a staining exam are quick and standardized. That simplicity shows up in the BVA data: dry eye carries one of the lower C&P-inadequate shares and one of the lower remand shares in the dataset, which is consistent with a condition where the examiner usually does have enough to work with.

Secondary Chains: Where Dry Eye Comes From

Dry eye is frequently a secondary condition rather than a standalone direct claim. Under 38 CFR § 3.310, secondary service connection can be granted for a condition caused by a service-connected condition or aggravated by one (Allen v. Brown). The chains that recur in dry eye claims:

Medication side effects. This is the most underused dry eye secondary. A long list of common medications causes or worsens dry eye: antidepressants (including SSRIs and tricyclics), antihistamines, and isotretinoin (Accutane) among them. If you take one of these for a service-connected condition, the dry eye that follows can be a secondary. The classic chain is service-connected PTSD or depression treated with an SSRI or other antidepressant, with dry eye as the downstream side effect. The nexus opinion has to identify the specific drug, the documented dry-eye side effect, and the temporal relationship to treatment.

Sjogren's syndrome. Sjogren's is an autoimmune disease whose hallmark is dry eyes and dry mouth from immune attack on the moisture-producing glands. Where Sjogren's is service-connected or itself secondary to a service-connected condition, the dry eye flows from it directly.

Chronic conjunctivitis or blepharitis. Chronic inflammation of the conjunctiva or the eyelid margins disrupts the tear film and the meibomian glands that produce its oily layer. Service-connected chronic conjunctivitis or blepharitis can produce or aggravate dry eye as a related ocular-surface process.

Refractive eye surgery. LASIK and similar corneal refractive procedures cut corneal nerves and are a well-recognized cause of post-surgical dry eye, sometimes chronic. Where the refractive surgery is connected to service, the resulting dry eye can follow.

For any of these chains, the nexus standard is the same. The opinion has to identify the mechanism, address the time course, and rule out unrelated causes. "Dry eye is related to the veteran's medications" without naming the drug, the documented side effect, and the timeline is not probative. A fully articulated opinion that walks the mechanism carries the case.

Common Evidence Gaps in Dry Eye Claims

A few patterns I have noticed across BVA decisions involving dry eye.

Symptoms documented, objective findings missing. The record shows repeated complaints of burning, grittiness, and watering, but no Schirmer test, no staining, no measured tear production. Without objective findings, the rater treats the condition as inactive and rates on residuals, which for an otherwise visually intact eye can mean non-compensable. The complaint and the objective finding are different things, and the rating runs on the finding.

Over-the-counter treatment instead of documented prescription burden. Artificial tears bought off the shelf rarely make it into the record as a treatment regimen, and they carry less evidentiary weight than prescription therapy. When a veteran has actually escalated to cyclosporine, punctal plugs, or serum tears, that regimen is strong evidence the disease is active and continuous, but only if it is documented in the file. An undocumented prescription history reads like mild, self-managed dryness.

The secondary chain is never raised. A veteran on a service-connected-condition medication that causes dry eye, or a veteran with service-connected Sjogren's, files the dry eye as a direct claim that fails on nexus, when it would have succeeded as a secondary under § 3.310. The medication or the upstream condition is in the file, but no one connects it.

Wrong analogous code applied. Because dry eye is rated by analogy, a rater can apply DC 6018 to a tear-system disorder that fits DC 6025 better, or vice versa, and rate the condition on criteria that do not match its dominant pathology. The medical evidence should make the mechanism explicit so the correct analogy gets used.

I do not know exactly what percentage of dry eye claims have one or more of these gaps. What I can say from Claim Raven's analysis of 500 BVA dry eye cases is that 46.4% were granted, 12.0% remanded, and 41.6% denied, and that of the 426 cases with a C&P adequacy determination, 26.3% had the exam flagged as inadequate. The remand share and the inadequate-exam share are both among the lower figures across the conditions I analyzed. That pattern fits a condition with relatively simple objective findings: the examiner usually has enough to decide, so the Board grants or denies outright more often than it sends the case back. The denials, in my read, cluster around the gaps above, especially missing objective findings and unraised secondary chains, rather than around exams that could not be performed.

Bottom Line

Dry eye syndrome does not have its own diagnostic code, so everything about the rating runs through the analogy to DC 6018 (chronic conjunctivitis) or DC 6025 (disorders of the lacrimal apparatus) under § 4.79. Two levers decide the outcome: whether the condition is active with objective findings on exam, and whether you need continuous treatment such as prescription drops, punctal plugs, or serum tears to control it. The claims that do well document both, with measured tear production and ocular-surface staining alongside a real prescription regimen, instead of a complaint of dryness managed with over-the-counter tears. And because dry eye is so often a side effect of medications taken for a service-connected condition, or a feature of Sjogren's, chronic conjunctivitis, or post-refractive-surgery change, the secondary chain under § 3.310 is frequently the stronger path than a direct claim. Same condition, different paper trail, different outcome.

Related Conditions

Dry eye claims sit alongside the other vision pages, and the same § 4.79 mechanics and objective-findings logic carry across them. Review cataracts, glaucoma, and diabetic retinopathy, which share the eye rating schedule and the same emphasis on measured findings over reported symptoms. If your dry eye traces back to a medication or an upstream condition, work through the secondary conditions tool before filing it as a direct claim, and use the evidence checklist and C&P exam prep tools so the Schirmer test, staining, and treatment regimen all make it into the record.

Methodology and Limitations

• Data source: Rating framework drawn from 38 CFR § 4.79, the schedule of ratings for the organs of special sense, with dry eye syndrome (keratoconjunctivitis sicca) rated by analogy under § 4.20, most often through DC 6018 (chronic conjunctivitis) or DC 6025 (disorders of the lacrimal apparatus). Secondary service connection from § 3.310. Secondary-aggravation principle from Allen v. Brown.
• Sample size: Patterns in this post are drawn from Claim Raven's analysis of 101,518 condition records drawn from the analyzed subset of Claim Raven's 501,000+ Board-decision library, including 500 dry eye cases. Within that subset, outcomes ran 46.4% granted, 12.0% remanded, and 41.6% denied. Of the 426 cases that carried a C&P adequacy determination, 26.3% had the examination flagged as inadequate, which is among the lower inadequate-exam and remand shares across the conditions analyzed.
• Classification approach: Code and analogy framework drawn from the regulatory text. Active-versus-inactive and one-eye-versus-both-eyes distinctions follow the structure of the eye rating schedule. Outcome and adequacy figures are direct queries against the BVA decision set.
• Limitations:
• I deliberately did not quote exact percentage tiers for DC 6018 or DC 6025. The eye schedule's active-disease and residuals structure makes an invented number risky. Read the current § 4.79 text for the operative figures and confirm what your rating decision applied.
• Because dry eye is rated by analogy, the controlling code can vary by case depending on the dominant pathology in the record.
• The dataset captures overall outcome and C&P adequacy rather than a per-diagnostic-code breakdown, so I cannot read a DC 6018 versus DC 6025 split directly from it.
• Selection bias: BVA-level patterns reflect cases that appealed. Most dry eye claims resolve at the RO level and are not in any BVA dataset.
• These observations reflect patterns from the regulatory text and BVA decisions. They are not predictions of individual outcomes.